Treatment of the MPS disorders primarily consists of supportive care and management of complications. Bone marrow transplant (BMT) and enzyme replacement are two promising therapies that offer the possibility of altering the course of these conditions
Mutations in the alpha-L-iduronidase (IDUA) gene located on chromosome 4 cause the MPS I disorders (Hurler, Hurler-Scheie, and Scheie syndromes
The MPS disorders are caused by absent or insufficient production of proteins known as lysosomal enzymes The specific enzyme that is deficient or absent distinguishes one type of MPS from another
Some examples of metabolic disorders inherited in an autosomal recessive manner include phenylketonuria (PKU), cystic fibrosis, and Tay-Sachs disease. In autosomal recessive inheritance, two copies of the abnormal gene are needed to manifest the disorder.
Common problems include abnormal heart valves, narrowing of the blood vessels in the heart, and weak heart muscles (cardiomyopathy). Patients with MPS I H and the severe form of MPS II usually have damage to the mitral valve
Patricia A. Prelock has written: 'Treatment of autism spectrum disorders' -- subject(s): Autism spectrum disorders in children, Autism spectrum disorders, Treatment
Treatment will depend on the cause of the swallowing problem.
when phosphorus is used in the treatment of blood disorders means then it is known as radio active phosphorus therapy.
Seizures are a problem found in severe forms of MPS and especially in MPS III (Sanfilippo syndrome). Patients with seizures are given a type of prescription medication known as an anticonvulsant.
Orthopaedics
It is the treatment of urinary tract and pelvic disorders
James R. Andrews has written: 'Family based treatment in communicative disorders' -- subject(s): Communicative disorders, Treatment
Vagus Nerve disorders can be solved in the sense that they can be treated. Nerve therapy or medical treatment in the form of surgery are the usual courses of treatment.